TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 responses in Vogt-Koyanagi-Harada disease
Purpose
To depict the genome-wide DNA 5-hmC and transcription profile and uncover aberrant hydroxymethylation modifications axis in VKH disease.
Methods
The 5-hmC-Seal-seq and RNA-seq were performed to uncover differential DNA5-hmC and transcription pattern. The global DNA 5-hmC level, TET activity, expression of TET family and differential hydroxymethylated genes, frequencies of Th1 cell and productions of Th-related cytokines in CD4+ T cells were detected.
Results
The global DNA 5-hmC level and the TET activity were elevated in association with the up-regulated expression of TET1 and TET2 in CD4+T cells from active VKH patients compared to healthy controls. A combined analysis of sequencing results showed that a total of 6 crucial genes were identified in CD4+T cells between active VKH patients and normal controls. The promoter 5-hmC and mRNA levels of leucine rich repeat containing 39 (LRRC39) were verified to be elevated in active VKH patients. Functional experiments showed that TET2 could up-regulate LRRC39 mRNA expression by increasing the promoter 5-hmC level of LRRC39 in active VKH CD4+ T cells. Up-regulated LRRC39 expression could not only increase the frequencies of IFN-γ+ CD4+ T cells as well as the secretions of IFN-γ.
Conclusion
This study reveals a novel axis, TET2–5-hmC-LRRC39–Th1 responses axis, in the pathogenesis of VKH disease and provides a potential target for further investigation into the prevention and treatment of this disease.
Conflict of interest
No
Authors 1
Last name
ZHANG
Initials of first name(s)
WY
Department
The First Affiliated Hospital of Chongqing Medical University
City
Chongqing
Country
China
Authors 2
Last name
YANG
Initials of first name(s)
PZ
Department
The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Ophthalmo
City
Chongqing
Country
China
This website uses cookies to ensure you get the best experience on our website.
Learn more